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Treatment of Full-Thickness Acetabular
Chondral Flaps During Hip Arthroscopy
Bone Marrow Aspirate Concentrate Versus Microfracture
Michael P. Kucharik,*,† BS, Paul F. Abraham,‡ MD, Mark R. Nazal,§ MD, MPH,
Nathan H. Varady,k MD, MBA, Christopher T. Eberlin,† BS, Wendy M. Meek,† BBA,
Sara A. Naessig,† BS, and Scott D. Martin,† MD
Investigation performed at Sports Medicine, Department of Orthopaedic Surgery, Massachusetts
General Hospital, Mass General Brigham, Boston, Massachusetts, USA
Background: The optimal treatment strategy for patients with full-thickness chondral flaps undergoing hip arthroscopy is
controversial.
Purpose: To compare functional outcomes of patients who underwent bone marrow aspirate concentrate (BMAC) application with
those of patients who underwent microfracture.
Study Design: Cohort study; Level of evidence, 3.
Methods: This was a retrospective case series of prospectively collected data on patients who underwent arthroscopic acetabular
labral repair by 1 surgeon between June 2014 and April 2020. The inclusion criteria for this study were age 18 years, preoperative
radiographs of the pelvis, arthroscopic acetabular labral repair, exposed subchondral bone with overlying chondral flap seen at the
time of hip arthroscopy, microfracture or BMAC to address this lesion, and completed patient-reported outcome measures
(PROMs) (International Hip Outcome Tool–33 [iHOT-33], Hip Outcome Score–Activities of Daily Living [HOS-ADL], Hip Outcome
Score–Sports Subscale [HOS-Sport], modified Harris Hip Score [mHHS], and visual analog scale [VAS] for pain) at enrollment and
12-month follow-up. Clinical outcomes were assessed using PROM scores.
Results: A total of 81 hips with full-thickness chondral flaps were included in this study: 50 treated with BMAC and 31 treated with
microfracture. There were no significant differences between groups in age, sex, body mass index, tear size, radiographic osteoarthritis, or radiographic femoroacetabular impingement. In the BMAC cohort, all PROM scores improved significantly from
preoperatively to follow-up: 41.7 to 75.6 for iHOT-33, 67.6 to 91.0 for HOS-ADL, 41.5 to 72.3 for HOS-Sport, 59.4 to 87.2 for mHHS,
and 6.2 to 2.2 for VAS pain (P < .001 for all). In the microfracture cohort, the score improvements were 48.0 to 65.1 for iHOT-33
(P ¼ .001), 80.5 to 83.3 for HOS-ADL (P ¼ .275), 59.2 to 62.4 for HOS-Sport (P ¼ .568), 70.4 to 78.3 for mHHS (P ¼ .028), and 4.9 to
3.6 for VAS pain (P ¼ .036). Regarding clinically meaningful outcomes, 77.6% of the BMAC group and 50.0% of the microfracture
group met the minimal clinically important difference for iHOT-33 at the 12-month follow-up (P ¼ .013).
Conclusion: Patients with full-thickness chondral flaps at the time of hip arthroscopy experienced greater improvements in
functional outcome scores at the 12-month follow-up when treated with BMAC as opposed to microfracture.
Keywords: hip arthroscopy; acetabular labral repair; chondral flap; bone marrow aspirate concentrate; microfracture

an overcovered acetabular rim.21 Initially, acetabular cartilage remains macroscopically intact, but it can eventually
become delaminated, fissured, and cracked—a manifestation that has been reported in 44% to 86% of patients with
FAI undergoing hip arthroscopy.3,13,22,30,35,37 In some cases,
the acetabular cartilage may completely rupture from
underlying subchondral bone starting in the periphery of the
joint and progressing centrally to form a full-thickness,
“outside-in” chondral flap.21,23 While severe, widespread cartilage delamination has been associated with poor clinical
outcomes after hip arthroscopy,18 the optimal treatment

Femoroacetabular impingement (FAI) has been associated
with hip pain, acetabular labral injuries, and chondral
lesions of the femoral head and acetabulum. 2 , 3 1 In
patients with combined FAI (concomitant cam and pincer
lesions), shearing forces during flexion and internal rotation cause an asymmetric femoral head to impinge against
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strategy for patients with isolated, full-thickness chondral
flaps is controversial.12,19,26,29,36,38,42
Currently, few clinical studies have compared functional
outcomes for different strategies for the treatment of fullthickness chondral flaps. Some studies have suggested that
chondral flaps serve as a source of impingement and their
removal by excision, debridement, or abrasion would allow
the lesion to heal itself over time.4,8,10 More recent studies
have advised the fixation of the flap using fibrin adhesive,
autologous scaffolding material, implanted collagen membrane, or underlying microfracture.12,20,26,38,42 These preservation techniques are theoretically ideal since chondral
flaps have been reported to contain up to 90% viable chondrocytes.29,43 However, the extracellular matrix (ECM) surrounding the viable chondrocytes is largely disturbed,
which warrants the use of a substance to bridge the chondral flap to subchondral bone to allow for long-term attachment and distribution of new ECM.24,43
While microfracture has shown favorable results in
treating patients with full-thickness chondral damage,11,25
some studies have suggested downsides, such as a weakened trabecular bone structure leading to an increased risk
of conversion to total hip arthroplasty (THA) with extended
follow-up.14,28 Accounting for these concerns, surgeons
could use bone marrow aspirate concentrate (BMAC) as a
method to bridge the chondral flap to subchondral bone
without violating the underlying trabecular bone. BMAC
has shown promising results for the treatment of other
chondral insults, and its utilization during hip arthroscopy
could potentially allow for long-standing reattachment of
biologically viable chondral flaps.1,5,7,40
The current study aimed to add to the growing body of
literature addressing strategies for the preservation of
full-thickness chondral flaps during hip arthroscopy by
reporting the utilization of BMAC as a unique technique
for fixation and comparing these results to those of patients
who underwent microfracture. We hypothesized that
patients with full-thickness chondral flaps treated with
BMAC application would report superior functional outcomes compared with similar patients treated with
microfracture.

METHODS
Study Population and Design
This study was approved by our institutional review board
and patients provided informed consent. Data for this study
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were prospectively collected and retrospectively reviewed.
All included patients underwent arthroscopic acetabular
labral repair by the senior surgeon (S.D.M.) between June
2014 and April 2020 and completed patient-reported outcome measures (PROMs) at enrollment and 12-month
follow-up. Inclusion criteria were age 18 years; preoperative radiographs of the pelvis; arthroscopic acetabular labral repair; and exposed subchondral bone with overlying
chondral flap seen at the time of hip arthroscopy, with
microfracture or BMAC to address this lesion. Exclusion
criteria were previous hip arthroscopy and arthroscopic
acetabular labral debridement.
All patients initially evaluated with hip pain at the
senior author’s (S.D.M.) clinic received hip and pelvis radiographs and a thorough physical examination, including
provocation testing of the labrum and evaluation for FAI
syndrome.15 Patients with positive findings on physical
examination (ie, pain and/or limited range of motion with
flexion, adduction, and internal rotation or flexion, abduction, and external rotation) underwent magnetic resonance
arthrogram; diagnostic/therapeutic intra-articular anesthetic/corticosteroid injection; and a trial of at least
3 months of nonoperative therapy, including corestrengthening physical therapy. Patients with persistent
hip pain despite nonoperative therapy were offered hip
arthroscopy.
The senior surgeon began utilizing BMAC in conjunction
with hip arthroscopy in December 2016 as a potential
method to address concomitant chondral lesions, and all
patients who underwent hip arthroscopy gave consent for
BMAC preoperatively from this point forward. Thus, the
patients who underwent arthroscopic acetabular labral
repair with concomitant microfracture to treat fullthickness chondral flaps between June 2014 and November
2016 were compared with similar patients treated with
BMAC between December 2016 and April 2020. For the
patients who received BMAC, the costs associated with harvesting and application were paid by the Conine Family
Fund for Joint Preservation (a philanthropy organization
without affiliations to industry); thus, patients’ ability to
pay played no role in their receiving BMAC. There were
no differences in surgical technique (other than microfracture vs BMAC), indications, means of data collection, or
rehabilitation between groups. Moreover, the senior surgeon had already completed >1000 hip arthroscopy procedures by the time of the first microfracture procedure, thus
mitigating any risk of expert bias.27
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Figure 1. Patient flowcharts for the (A) 31 hips treated with microfracture and (B) 50 hips treated with BMAC included in the study.
PROMs, patient-reported outcome measures.

Data Collection
Patient and descriptive data, including age, sex, laterality,
body mass index (BMI), Tönnis grade, and radiographic
evidence of FAI, were collected. Intraoperatively, tear size
was recorded based on the extent of a clock face converted
to degrees. Patients in both cohorts prospectively completed the following PROMs at enrollment before surgery
and at 3-, 6-, and 12-month follow-up visits: International
Hip Outcome Tool–33 (iHOT-33), Hip Outcome Score–
Activities of Daily Living (HOS-ADL), Hip Outcome
Score–Sports Subscale (HOS-Sport), modified Harris Hip
Score (mHHS), and visual analog scale (VAS) for pain.
Patients were only included for data analysis if they completed PROMs at enrollment and at the 12-month followup. Clinically meaningful outcomes were assessed by calculating the percentage of patients who reached threshold
PROM scores for minimal clinically important difference
(MCID), patient acceptable symptom state (PASS), and
substantial clinical benefit (SCB), as defined by Nwachukwu et al.33

Surgical Technique
The technique of surgical arthroscopic acetabular labral
repair using a chondrolabral junction preservation technique
with intermittent traction and possible FAI decompression
has been described in previous technical notes.6,34,39 Once
adequate intra-articular visualization of the lesion was
established, a blunt obturator probe was used to evaluate
the extent of the labral tear, extension of the tear into the
chondrolabral junction, and presence of a chondral flap
overlying subchondral bone. Notably, acetabular labral
repair was performed before microfracture or BMAC harvesting and application. For patients who underwent
microfracture, a 60 microfracture Steadman awl was utilized to carry out perpendicular microfracture into the
subchondral plate behind the flap. For patients who

underwent BMAC,32 processing (Arthrex) and application
of BMAC were carried out as described in a previous technical note.40 For all patients in the BMAC cohort, a BMAC
megaclot, composed of 20 mL of platelet-poor plasma/
platelet-rich plasma and 4 mL of BMAC along with thrombin for adequate coagulation, was applied into the central
compartment of the hip. After arthroscopic acetabular labral repair and microfracture or BMAC, traction was
released, and the hip was placed through a full range of
motion to ensure restored labral seal as well as excellent
stability of the flap.

Postoperative Rehabilitation
Patients in both cohorts received the same postoperative
protocol. Patients were allowed immediate weightbearing
as tolerated using a flat-footed gait with crutches for
6 weeks. At 6 weeks postoperatively, patients could start
using a stationary bicycle. At 10 weeks, patients were
allowed to swim or use an elliptical trainer. At 4 months,
strengthening exercises including hamstring curls and
short-arc leg press with low weight and high repetitions
were encouraged. At 6 months, patients were permitted to
resume impact-loading exercises as tolerated.

Statistical Analysis
Baseline patient factors were compared between the groups
using t test or chi-square/Fisher exact test, as appropriate.
A 2-tailed paired t test was used to assess differences
between preoperative and postoperative scores for the individual groups. Consistent with the repeated-measures data
structure, an independent-samples t test was used to compare mean changes in PROMs between the BMAC and
microfracture groups. The primary outcome was the mean
iHOT-33 score improvement at the 12-month follow-up. All
statistics were computed using SPSS statistical software
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TABLE 1
Preoperative and Intraoperative Characteristics for the
BMAC and Microfracture Groupsa

Age, y
Sex
Male
Female
Laterality
Right
Left
BMI
Tear size, deg
Tönnis grade
0
1
2
FAI
None
Pincer
Cam
Combined

BMAC
(n ¼ 50 hips)

Microfracture
(n ¼ 31 hips)

32.8 (29.8-35.8)

35.9 (31.7-40.1)

31 (62.0)
19 (38.0)

BMAC

22 (44.0)
25 (50.0)
3 (6.0)

7 (22.6)
21 (67.7)
3 (9.7)

1 (2.0)
19 (38.0)
2 (4.0)
28 (56.0)

2 (6.4)
14 (45.2)
4 (12.9)
11 (35.5)

P
P
Mean (95% CI) Value Mean (95% CI) Value

.242
.949

19 (61.3)
12 (38.7)
17 (54.8)
14 (45.2)
25.3 (23.9-26.7)
67.2 (58.2-76.2)

Microfracture

P Value

.941
27 (54.0)
23 (46.0)
25.4 (24.3-26.5)
69.3 (63.8-74.8)

TABLE 2
Comparison of Preoperative and 12-Month Postoperative
PROMs Within the BMAC and Microfracture Groupsa

.913
.689
.145

.173

a

Continuous variables are reported as mean (95% CI), and
categorical variables are reported as n (%). BMAC, bone marrow
aspirate concentrate; BMI, body mass index; FAI, femoroacetabular
impingement.

iHOT-33
Preoperative
12-mo follow-up
HOS-ADL
Preoperative
12-mo follow-up
HOS-Sport
Preoperative
12-mo follow-up
mHHS
Preoperative
12-mo follow-up
VAS pain
Preoperative
12-mo follow-up

< .001
41.7 (36.7-46.7)
75.6 (70.7-80.5)
67.6 (62.2-73.1)
91.0 (88.6-93.4)
41.5 (34.5-48.4)
72.3 (64.9-79.7)
59.4 (55.2-63.6)
87.2 (84.2-90.1)
6.2 (5.4-6.8)
2.2 (1.5-2.8)

< .001
< .001
< .001
< .001

.001
48.0 (41.3-54.8)
65.1 (56.7-73.5)
.275
80.5 (74.9-86.2)
83.3 (77.0-89.6)
.568
59.2 (51.8-66.5)
62.4 (51.4-73.3)
.028
70.4 (66.2-74.6)
78.3 (72.6-84.0)
.036
4.9 (4.0-5.9)
3.6 (2.7-4.6)

a

Bolded P values indicate a statistically significant improvement from preoperatively to follow-up (P < .05). BMAC, bone marrow aspirate concentrate; HOS-ADL, Hip Outcome Score–
Activities of Daily Living; HOS-Sport, Hip Outcome Score–Sports
Subscale; iHOT-33, International Hip Outcome Tool–33; mHHS,
modified Harris Hip Score; PROMs, patient-reported outcome
measures; VAS, visual analog scale.

(version 27.0.0; IBM Corp), and P < .05 was considered
significant.

RESULTS
A total of 81 hips (81 patients) were included in this
study: 50 treated with BMAC and 31 treated with microfracture group (Figure 1). Baseline characteristics were
not significantly different between patients in the
BMAC and microfracture groups (Table 1). Notably,
PROMs for all patients were collected from their 12month follow-up surveys. In terms of disenrollment,
86.2% and 86.1% of patients with BMAC and microfracture completed PROMs at the 12-month follow-up,
respectively.
In the BMAC cohort, all scores improved significantly
from preoperatively to the 12-month follow-up: 41.7 to
75.6 for iHOT-33, 67.6 to 91.0 for HOS-ADL, 41.5 to 72.3
for HOS-Sport, 59.4 to 87.2 for mHHS, and 6.2 to 2.2 for
VAS pain (P < .001 for all). In the microfracture cohort,
significant improvements were seen in the iHOT-33 (48.0
to 65.1; P ¼ .001), mHHS (70.4 to 78.3; P ¼ .028), and VAS
pain (4.9 to 3.6; P ¼ .036) (Table 2).
When comparing results between groups, we found that
at baseline, patients who underwent BMAC and microfracture had similar mean iHOT-33 scores (41.7 vs 48.0;
P ¼ .127), and the BMAC group had nonsignificantly higher
mean iHOT-33 scores at the 3-month (63.0 vs 55.4;
P ¼ .066) and 6-month (70.3 vs 62.4; P ¼ .075) follow-up
visits. However, at the 12-month follow-up, the BMAC

cohort had significantly higher mean iHOT-33 scores compared with the microfracture cohort (75.6 vs 65.1; P ¼ .025)
(Table 3).
In terms of improvement in mean iHOT-33 scores, the
BMAC cohort reported significantly greater improvements
from baseline at the 3-month (22.0 vs 7.9; P ¼ .004),
6-month (27.7 vs 13.8; P ¼ .010), and 12-month (33.9 vs
15.2; P < .001) follow-up visits (Table 4).
For HOS-ADL, despite significantly lower baseline
scores for the BMAC cohort (68.2 vs 79.1; P ¼ .007), the
BMAC cohort still outperformed the microfracture cohort
at the 12-month follow-up (91.0 vs 83.3; P ¼ .032). Similarly, the BMAC cohort reported significantly lower mean
mHHS values at baseline (59.4 vs 70.6; P ¼ .001) but significantly higher mean mHHS values at the 12-month
follow-up (87.2 vs 78.3; P ¼ .003). Moreover, the BMAC
cohort reported lower mean VAS scores at the 12-month
follow-up (2.2 vs 3.6; P ¼ .012), despite higher mean pain
scores preoperatively (6.1 vs 5.0; P ¼ .072).
In terms of clinically meaningful outcomes, 77.6% and
50.0% of hips treated with BMAC application and microfracture achieved 12-month improvements in iHOT-33
scores that reached the MCID threshold, respectively
(P ¼ .013). Otherwise, the only significant differences
between groups for PASS and SCB were the mHHS: BMAC,
58.0% versus microfracture, 25.0% (P ¼ .008) for PASS and
BMAC, 56.0% versus microfracture, 25.0% (P ¼ .012) for
SCB (Table 5).
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TABLE 3
Comparison of PROM Scores Over Time Between the
BMAC and Microfracture Groupsa
BMAC

Microfracture

TABLE 4
Comparison of Changes From Baseline in PROM Scores
Between the BMAC and Microfracture Groupsa

P Value
BMAC

Enrollment
iHOT-33
HOS-ADL
HOS-Sport
mHHS
VAS pain
3-mo follow-up
iHOT-33
HOS-ADL
HOS-Sport
mHHS
VAS pain
6-mo follow-up
iHOT-33
HOS-ADL
HOS-Sport
mHHS
VAS pain
12-mo follow-up
iHOT-33
HOS-ADL
HOS-Sport
mHHS
VAS pain

n ¼ 50
41.7 (36.9-46.5)
68.2 (62.8-73.6)
42.4 (35.6-49.1)
59.4 (55.2-63.6)
6.1 (5.4-6.8)
n ¼ 44
63.0 (58.6-67.3)
82.2 (78.4-85.9)
43.6 (35.0-52.3)
77.6 (74.1-81.2)
2.7 (2.0-3.3)
n ¼ 46
70.3 (65.6-75.0)
87.4 (84.0-90.7)
63.6 (55.6-71.6)
81.4 (77.8-85.1)
2.4 (1.8-3.1)
n ¼ 50
75.6 (70.7-80.5)
91.0 (88.6-93.4)
72.3 (64.9-79.7)
87.2 (84.2-90.1)
2.2 (1.5-2.8)

n ¼ 31
(41.3-54.8)
(73.6-84.6)
(48.8-64.1)
(66.3-75.0)
(4.1-6.0)
n ¼ 23
55.4 (48.4-62.5)
74.6 (67.8-81.4)
28.5 (19.2-37.8)
72.6 (67.2-78.1)
3.0 (2.1-3.9)
n ¼ 22
62.4 (54.9-70.0)
81.5 (75.9-87.1)
51.0 (40.7-61.2)
76.8 (71.0-82.6)
3.0 (2.0-3.9)
n ¼ 31
65.1 (56.7-73.5)
83.3 (77.0-89.6)
62.4 (51.4-73.3)
78.3 (72.6-84.0)
3.6 (2.7-4.6)
48.0
79.1
56.4
70.6
5.0

.127
.007
.010
.001
.072
.066
.042
.032
.127
.526
.075
.067
.071
.177
.377
.025
.032
.132
.003
.012

a
Data are reported as mean (95% CI). Bolded P values indicate
a statistically significant difference between groups (P < .05).
BMAC, bone marrow aspirate concentrate; HOS-ADL, Hip Outcome Score–Activities of Daily Living; HOS-Sport, Hip Outcome
Score–Sports Subscale; iHOT-33, International Hip Outcome
Tool–33; mHHS, modified Harris Hip Score; PROM, patientreported outcome measure; VAS, visual analog scale.

DISCUSSION
In the current study, both BMAC and microfracture cohorts
experienced significant improvements in mean iHOT-33
score from baseline to the 12-month follow-up; however, the
BMAC cohort outperformed the microfracture cohort at 12
months in terms of raw score and improvement at statistically significant levels. Moreover, the difference between
groups at the 12-month follow-up was clinically meaningful, as a higher percentage of patients in the BMAC cohort
achieved improvements that met the MCID threshold for
iHOT-33 scores.33
That BMAC and microfracture cohorts experienced significant improvements from baseline is not surprising, as
previous studies have reported positive results for other
techniques that can preserve chondral flaps that contain
up to 90% viable chondrocytes.17,29,36,43 As described by
Levinson et al,24 the difficulty with preservation of the flap
has been more so related to maintaining the integrity of the
ECM around the chondrocytes. Once the chondral flap ruptures from the underlying subchondral bone, the ECM
becomes disturbed, and remaining chondrocytes are unable
to deposit new ECM regardless of their proximity to adjacent bone.24,43 This phenomenon served as the impetus for

5

3-mo follow-up
D iHOT-33
D HOS-ADL
D HOS-Sport
D mHHS
D VAS
6-mo follow-up
D iHOT-33
D HOS-ADL
D HOS-Sport
D mHHS
D VAS
12-mo follow-up
D iHOT-33
D HOS-ADL
D HOS-Sport
D mHHS
D VAS

22.0
15.3
4.2
18.1
–3.4
27.7
18.4
19.4
20.4
–3.5
33.9
23.4
30.8
27.8
–4.0

Microfracture

n ¼ 44
n ¼ 23
(16.6 to 27.4)
7.9 (0.1 to 15.8)
(10.2 to 20.3) –3.5 (–12.6 to 5.5)
(–4.1 to 12.4) –25.0 (–35.7 to –14.2)
(12.9 to 23.2)
1.6 (–5.5 to 8.8)
(–4.2 to –2.5) –1.9 (–3.0 to –0.8)
n ¼ 46
n ¼ 22
(21.8 to 33.5) 13.8 (5.3 to 22.2)
(12.6 to 24.1)
2.9 (–2.3 to 8.2)
(9.6 to 29.2)
–4.9 (–15.4 to 5.5)
(14.9 to 26.0)
6.4 (–0.2 to 12.8)
(–4.3 to –2.6) –1.7 (–2.7 to –0.6)
n ¼ 50
n ¼ 31
(27.8 to 40.0) 15.2 (6.9 to 23.5)
(18.0 to 28.8)
2.8 (–2.1 to 7.7)
(21.8 to 39.8)
3.1 (–7.6 to 13.8)
(22.5 to 33.0)
7.8 (1.2 to 14.4)
(–4.8 to –3.1) –1.3 (–2.1 to –0.4)

P
Value

.004

< .001
< .001
< .001
.040
.010

< .001
.004
.004
.018

< .001
< .001
< .001
< .001
< .001

a

Data are reported as mean (95% CI). Bolded P values indicate
a statistically significant difference between groups (P < .05).
BMAC, bone marrow aspirate concentrate; HOS-ADL, Hip Outcome Score–Activities of Daily Living; HOS-Sport, Hip Outcome
Score–Sports Subscale; iHOT-33, International Hip Outcome
Tool–33; mHHS, modified Harris Hip Score; PROM, patientreported outcome measure; VAS, visual analog scale for pain.

the evolution of surgical techniques to replace functional
ECM to act as a bridge between viable chondrocytes and
exposed subchondral bone.12,26,38,42 Thus, techniques such
as BMAC, microfracture, or a fibrin adhesive would be ideal
strategies to reduce the chondral flap and restore its native
anatomy while maintaining the survival of viable
chondrocytes.
The current study adds to the growing body of literature
regarding treatment strategies for full-thickness chondral
flaps. Haefeli et al16 found that subchondral drilling under
the chondral flap decreased the rate of conversion to THA
when compared with simple debridement of the chondral
flap. Similarly, Hevesi et al19 compared microfracture and
debridement and reported mHHS, HOS-Sport, and VAS
improvements that were similar to those of the microfracture cohort in our study. However, Hevesi et al19 did not
find a statistically significant difference between groups
in terms of functional outcomes or long-term survival
with a follow-up of 5 years. Similar to the current study,
Ivone et al20 found that the microfragmented autologous
adipose tissue transplantation technique group reported
a final mHHS that outperformed the microfracture cohort
by >1 MCID threshold. Tahoun et al41 utilized a chitosanbased scaffold (BST-CarGel) alongside microfracture and
found that >90% of patients demonstrated complete restoration of the cartilage defect on magnetic resonance
imaging scans with specific cartilage sequences. Lastly,
Tzaveas and Villar42 utilized a fibrin adhesive without
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TABLE 5
Comparison of Clinically Meaningful Outcomes Between
the BMAC and Microfracture Groupsa

MCID
iHOT-33
HOS-ADL
HOS-Sport
mHHS
PASS
iHOT-33
HOS-ADL
HOS-Sport
mHHS
SCB
iHOT-33
HOS-ADL
HOS-Sport
mHHS

BMAC

Microfracture

P Value

38 (77.6)
33 (66.0)
37 (77.1)
42 (84.0)

14 (50.0)
7 (25.0)
10 (35.7)
13 (48.1)

< .001
< .001
< .001

32 (66.7)
33 (67.3)
29 (60.4)
29 (58.0)

14 (56.0)
14 (56.0)
12 (48.0)
6 (25.0)

.206
.183
.310
.008

27 (56.3)
33 (67.3)
24 (50.0)
28 (56.0)

10 (40.0)
14 (56.0)
12 (48.0)
6 (25.0)

.243
.450
.871
.012

.013

a

Data are reported as No. of patients (%). Bolded P values indicate a statistically significant difference between groups (P < .05).
BMAC, bone marrow aspirate concentrate; HOS-ADL, Hip Outcome Score–Activities of Daily Living; HOS-Sport, Hip Outcome
Score–Sports Subscale; iHOT-33, International Hip Outcome
Tool–33; MCID, minimal clinically important differences; mHHS,
modified Harris Hip Score; PASS, patient acceptable symptom
state; SCB, substantial clinical benefit.

microfracture and reported significantly improved clinical outcomes when compared with baseline scores. While
microfracture in the aforementioned studies was reported
as safe, some studies have found a greater long-term progression to THA and revision arthroscopy in patients
undergoing microfracture of the hip than in a control
cohort.9,11,25 Thus, our study introduces an alternative
technique for preservation of the chondral flap with better
short-term clinical outcomes when compared with a standard treatment that has been associated with a long-term
risk of conversion to THA.
While this study has several strengths, including its
large sample of patients undergoing hip arthroscopy with
BMAC treatment for full-thickness chondral flaps with prospectively collected outcome measures and its utilization of
a similar control cohort for comparison, it is not without
limitations. First, patients who received BMAC or microfracture did not undergo postoperative magnetic resonance
imaging, which could have been used to assess cartilage
healing after surgical intervention. Second, while the surgeon was highly experienced at the time the first patient
underwent microfracture and there were no differences in
surgical technique or rehabilitation between cohorts, unobserved confounders that occurred over time may have contributed to the results. Third, as is the case with survey
studies, loss to follow-up and unanswered questionnaires
serve as a potential source of bias. Importantly, this source
of bias should not differ between groups, as methods of

enrollment and survey collection have not changed since
the first patient who underwent microfracture. Fourth,
while patients in the BMAC cohort experienced greater
PROM improvements than did those who underwent microfracture, it is important to note that patients who underwent microfracture had higher scores preoperatively, albeit
at a statistically insignificant level. While this may have
potentially affected the percentage of patients who reached
MCID, the BMAC cohort still reported significantly greater
iHOT-33 scores at the 12-month follow-up, despite starting
at lower baseline scores. Fifth, BMAC harvesting and application during hip arthroscopy is a relatively novel procedure and, thus, is unavailable to many patients because of
financial or logistical limitations. Sixth, because of the novelty of BMAC for the treatment of full-thickness chondral
flaps, long-term follow-up is needed to determine sustainable outcomes and progression to THA. Notably, the results
of the current study are preliminary and merely suggest an
alternative treatment option for full-thickness chondral
flaps, as the microfracture cohort still experienced significant improvements, which is consistent with results in the
current literature.

CONCLUSION
Patients with full-thickness chondral flaps at the time of
hip arthroscopy experienced greater improvements in functional outcome scores at the 12-month follow-up when treated with BMAC as opposed to microfracture. These findings
are preliminary, and future, high-level studies examining
the long-term utility of BMAC for the treatment of chondral
flaps are needed.
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